Heart Disease Trial, Recruiting NCT06675552 Sponsor: AstraZeneca Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06675552
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older at the time of signing the consent form
  • People who are currently admitted to a participating hospital and receiving full inpatient care, with a stay of at least 24 hours
  • People who have been diagnosed with a type of heart failure where the heart pumps weakly (known as HFrEF), with the heart's pumping ability measured at 40% or less on an ultrasound scan, either during this hospital stay or within the 3 months before it
  • People who are currently taking no more than 2 of the 4 main recommended heart failure medication types at the time of admission (confirm with trial site for exact medication details)
  • People who are willing and able to give signed, dated consent before joining the study
  • People who are willing and able to follow all the requirements outlined in the consent form

Who may not be able to join:

  • People whose current hospital admission involved a severe state of shock, including cardiogenic shock
  • People who have previously had a heart transplant
  • People who have had serious intolerances or side effects to certain heart failure medication types that caused them to stop taking them, under specific conditions (confirm with trial site for exact details)
  • People who are currently taking part in, or planning to join, another clinical trial
  • People where the trial doctor has decided participation would not be appropriate, such as if the person is unlikely to be able to follow the study procedures
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
15 November 2024
Est. completion
30 June 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Proportion of patients treated with HFrEF GDMT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov